Kinetics of HER2/neu ECD in 45 patients treated with trastuzumab (Herceptin®) between January 2001 and June 2005 at the Grenoble University Hospital

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1703-1707

  Gauchez, Anne Sophie ^a,d   Colonna, Marc ^b   Brand, François Xavier ^a   Ravanel, Nadia ^a   Pasquier, Dominique ^a   Payan, Raoul ^c   Mousseau, Mireille ^a,d  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Isere Cancer Registry   (France)

^c Belledonne Clinical Center   (France)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

Breast cancer; HER2 neu ECD; Kinetics; Trastuzumab; Tumor marker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NEOPLASM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GENES, ERBB-2; HUMANS; KINETICS; MIDDLE AGED; SWEDEN;

EID: 67650073219     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Singer CF, Köstler WJ and Hudelist G: Predicting the efficacy of trastuzumab-based therapy in breast cancer. Current standards and future strategies. Biochim Biophys Acta 1786(2): 105-113, 2008.
2. Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R and Mousseau M: Prospect for anti-Her2 receptor therapy in breast cancer. Anticancer Res 26(1): 715-722, 2006. (Pubitemid 43206039)
3. Dieras V, Vincent-Salomon A, Degeorges A, Beuzoboc P, Mignot L and De Crémoux P: Trastuzumab (Herceptin®) et cancer du sein: mécanismes de résistance. Bull Cancer 94(3): 25-66, 2007.
4. Jones SE: Consideration in the treatment choice for metastatic breast cancer. Breast Cancer 15(1): 35-39, 2008.
5. Köstler WJ, Schwab B, Singer CF, Neuman R, Rücklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger CG, Krainer M, Wiltschke C and Zielinski CC: Monitoring of serum Her-2/neu predicts response and progression-free survival to Trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10(5): 1618-1624, 2004. (Pubitemid 38435551)
6. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC and the Cancer and Leukemia Group B: Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7: 2703-2711, 2001. (Pubitemid 32911374)
7. Carney WP et al: Potential clinical utility of serum HER-2/neu oncoprotein concentration in patients with breast cancer. Clin Chem 49(10): 1579-1598, 2003. (Pubitemid 37194212)
8. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L and Cristofanilli M: Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109(3): 496-501, 2007. (Pubitemid 46190957)
9. Gauchez AS, Ravanel N, Villemain D, Brand FX, Pasquier D, Payan R and Mousseau M: Evaluation of a manual ELISA kit for determination of HER2/neu in serum of breast cancer patients. Anticancer Res 28(B): 3067-3073, 2008.
10. Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L and Hudis C: Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridisation and with response rate. Ann Oncol 16: 234-239, 2005. (Pubitemid 40309302)
11. Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras JL and Pichon MF: Serum HER-2 extracellular domain relationship with clinico-biological presentation and prognostic value before and after treatment in 701 breast cancer patients. Int J Biol Markers 19(1): 14-22, 2004. (Pubitemid 38515007)
12. Liu X, Fridman JS, Wang Q, Caulder E, Yang G, Covington M, Liu C, Marando C, Zhuo J, Li Y, Yao W, Vaddi K, Newton RC, Scherle PA and Friedman SM: Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther 5(6): 648-656, 2006. (Pubitemid 44024720)
13. Chiang CT, Way TD, Tsai SJ and Lin JK: Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in Her2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Letter 581(30): 5735-5742, 2007.
14. Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A and the Serum HER-2/neu Study Group: Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 113(6): 1294-1301, 2008.